Frangos Savvas, Iakovou Ioannis P, Marlowe Robert J, Eftychiou Nicolaos, Patsali Loukia, Vanezi Anna, Savva Androulla, Mpalaris Vassilis, Giannoula Evanthia I
Department of Nuclear Medicine, Bank of Cyprus Oncology Centre, 32 Acropoleos Avenue, Strovolos, Nicosia, 2006, Cyprus.
Department of Nuclear Medicine, Aristotle University, Papageorgiou Hospital, 56403, Thessaloniki, Greece.
Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):2045-55. doi: 10.1007/s00259-015-3124-4. Epub 2015 Aug 1.
We determined the reasons for radioiodine thyroid remnant ablation, and the procedure's necessity based on postsurgical remnant size, in patients with putatively "low-intermediate-risk" differentiated thyroid carcinoma (DTC). We identified key clinicopathological, treatment and remnant characteristics, and factors associated with remnant size in 336 patients with pT1/2, M0 DTC ablated during the period September 2010 to October 2013 at one Cypriot or one Greek referral centre.
Clinicopathological/treatment characteristics were compiled from charts. Experienced nuclear medicine physicians rated the numbers/intensities of uptake foci in the thyroid bed on postablation planar scintigrams using scales of 0-4 points and 0-3 points, respectively. The product of these scores was taken as the "remnant score" that ranged from 0 (no remnant) to 12 (multiple remnants, intense uptake).
DTC was predominantly papillary. The median [25th-75th percentile] longest primary tumour diameter was 1.0 cm [0.7-1.5 cm]. Despite favourable histotypes and primary tumour classifications, patients often had preablation characteristics suggesting elevated or uncertain risk: 31.0% of patients (104 of 336) had primary tumour multifocality, 22.0% (74) had confirmed cervical lymph node metastases, 37.2% (125) had unknown nodal status, and 38.1% (128) had antithyroglobulin antibody seropositivity. The median [25th-75th percentile] remnant score was 4 [2-6]; 39.9% of patients (134 of 336) had scores ≥6. For the entire cohort, T or N stages (r ≤ 0.174, P ≤ 0.05) correlated positively with the remnant score in a univariate Spearman analysis. The numbers of patients referred by the surgeon, cervical lymph nodes excised and metastatic nodes excised correlated negatively (r ≤ 0.243, P ≤ 0.038) with the remnant score, and the first two factors independently predicted the remnant score (P ≤ 0.037) in a multivariate analysis.
Patients with putatively "low-intermediate-risk" DTC frequently had disease characteristics denoting high or uncertain risk, suggesting that "selective" radioiodine ablation in such patients may seldom be applicable outside international centres of excellence. Proxies for surgeon experience and surgical completeness correlated with remnant number/uptake intensity and may aid ablation-related decision-making.
我们确定了在假定为“低-中危”的分化型甲状腺癌(DTC)患者中,进行放射性碘甲状腺残余组织消融的原因,以及基于术后残余组织大小的该操作的必要性。我们在2010年9月至2013年10月期间,于塞浦路斯或希腊的一家转诊中心,对336例pT1/2、M0期DTC患者进行消融治疗,确定了关键的临床病理、治疗及残余组织特征,以及与残余组织大小相关的因素。
从病历中收集临床病理/治疗特征。经验丰富的核医学医生分别使用0 - 4分和0 - 3分的量表,对消融后平面闪烁扫描图上甲状腺床摄取灶的数量/强度进行评分。这些分数的乘积作为“残余组织评分”,范围从0(无残余组织)到12(多个残余组织,摄取强烈)。
DTC主要为乳头状癌。原发肿瘤最长径的中位数[第25 - 75百分位数]为1.0 cm[0.7 - 1.5 cm]。尽管组织学类型和原发肿瘤分类良好,但患者在消融前常有提示风险升高或不确定的特征:31.0%的患者(336例中的104例)有原发肿瘤多灶性,22.0%(74例)有确诊的颈部淋巴结转移,37.2%(125例)淋巴结状态不明,38.1%(128例)抗甲状腺球蛋白抗体血清学阳性。残余组织评分的中位数[第25 - 75百分位数]为4[2 - 6];39.9%的患者(336例中的134例)评分≥6。在单因素Spearman分析中,对于整个队列,T或N分期(r≤0.174,P≤0.05)与残余组织评分呈正相关。外科医生转诊的患者数量、切除的颈部淋巴结数量和切除的转移淋巴结数量与残余组织评分呈负相关(r≤0.243,P≤0.038),在前两个因素在多因素分析中独立预测残余组织评分(P≤0.037)。
假定为“低-中危”的DTC患者常有表示高风险或不确定风险的疾病特征,这表明在此类患者中进行“选择性”放射性碘消融在国际卓越中心之外可能很少适用。外科医生经验和手术完整性的指标与残余组织数量/摄取强度相关,可能有助于消融相关决策。